What Are the Risks of Exosome Therapy?

Exosome therapy carries several documented risks, most tied to how a product is sourced and manufactured rather than to the biology of exosomes themselves. The FDA has linked unapproved exosome and umbilical-cord-derived products to serious infections, and no exosome product currently holds FDA approval for any use (FDA, 2019; FDA, 2024). Reported reactions include injection-site irritation, infection, and allergic response, and long-term human safety data remains limited (Maher & Gold, 2026).

What This Means

Exosomes are tiny, membrane-bound particles released by cells — including mesenchymal stem cells — that carry proteins, lipids, and genetic material between cells (Mahmoud et al., 2025). Clinics have begun offering exosome injections for joint pain, hair loss, and skin concerns, often marketed as a needle-free alternative to more invasive procedures. But "exosome therapy" is not one standardized product. Formulations vary widely by source tissue, manufacturing process, and purity, and that variability is itself a safety concern (Maher & Gold, 2026).

Understanding the risks starts with understanding what regulators have and have not confirmed. No exosome product has FDA approval for any indication, and the agency classifies exosomes intended for use in disease as biologic drugs subject to full premarket review (FDA, 2024).

Candidacy

Because no exosome product is FDA-approved, there is no standard candidate profile the way there might be for an approved drug. In practice, physicians who discuss exosome-based options do so as part of a broader musculoskeletal or aesthetic evaluation, weighing a patient's history, prior procedures, allergies, and goals before any product is considered. Patients with an active infection, a bleeding disorder, or a known allergy to biologic components are generally not appropriate candidates, and pregnant or breastfeeding patients are typically excluded given the absence of safety data in those groups.

Clinical Evaluation

A responsible evaluation for exosome-based options includes a physical exam, a review of imaging and prior procedures, and a direct conversation about the product's source, manufacturer, and regulatory status. Patients should ask whether the clinic can name the tissue bank or manufacturer, whether the product has a Certificate of Analysis confirming sterility and exosome content, and whether the clinic operates under an FDA Investigational New Drug (IND) application. A clinic unwilling or unable to answer these questions directly is a signal worth taking seriously.

Available Options

Patients considering exosome injections have several other paths depending on the condition involved. For joint and musculoskeletal complaints, options include physical therapy, corticosteroid or hyaluronic acid injections, platelet-rich plasma (PRP), and an orthopedic surgical consultation. For hair loss, FDA-cleared low-level laser devices and prescription medications such as minoxidil and finasteride are established options. For skin concerns, in-office procedures like microneedling, laser resurfacing, and FDA-cleared collagen stimulators have a longer track record and a clearer regulatory pathway. None of these alternatives comes with a guaranteed outcome, and each carries its own risk profile that should be reviewed individually with a physician.

Benefits, Limitations and Risks

Proponents point to a favorable safety signal in small, controlled studies — for example, early trials of exosomes for inflammatory or wound-related conditions have reported few product-related adverse events (Mahmoud et al., 2025). But that evidence is preliminary, and it does not extend to the products sold in most U.S. clinics, which are frequently unregulated and inconsistently characterized.

The documented risks are substantial. The FDA has linked unapproved exosome and umbilical-cord-blood-derived products to serious bacterial bloodstream infections, joint infections, and epidural abscesses in patients across multiple states (Perkins et al., 2018). Because these products cannot be sterilized after collection, contamination introduced during manufacturing cannot be removed later, and outbreak investigators traced infections back to specific production lots (Perkins et al., 2018). Beyond infection, adverse events reported with unapproved exosome and regenerative products include allergic reactions, injection-site inflammation, and product content that does not match what was marketed. Some products labeled as containing exosomes, for example, have tested as little more than conditioned cell-culture media with minimal actual exosome content (Maher & Gold, 2026). These are real limitations, not minor caveats, and they should factor directly into any decision.

What the Evidence Shows

The evidence base does establish a few things clearly. It establishes that exosomes exist as a biological mechanism cells use to communicate, and that early-phase research is examining their use in inflammatory, orthopedic, dermatologic, and wound-healing contexts (Mahmoud et al., 2025). It establishes that no exosome product currently has FDA approval for any human use (FDA, 2024). And it establishes, through direct outbreak investigation, that contaminated regenerative products have caused documented, hospitalization-requiring infections (Perkins et al., 2018).

What the evidence does not establish is standardized outcomes for any specific condition, long-term safety data beyond a period of months to a couple of years, or consistency between what a given clinic markets and what a product actually contains. Patients should view marketing claims of guaranteed results, "stem cell strength," or FDA approval with real skepticism until they can verify those claims directly with the clinic and, where possible, independently.

Recovery / Next Steps

Because exosome products are administered by injection, most patients experience some injection-site soreness, redness, or mild swelling that typically resolves within a few days. Any sign of infection — fever, spreading redness, increasing pain, or drainage at the injection site — warrants prompt medical attention rather than a wait-and-see approach. Patients who move forward with any regenerative option, exosome-based or otherwise, should ask their physician for a written record of the product source and lot number, so that information is available if a reaction occurs later.

Orlando Considerations

Florida regulates who may administer orthobiologic and regenerative products and under what conditions, most recently through Florida Statute § 458.3245, which sets informed-consent and physician-oversight requirements for these procedures (Fla. Stat. § 458.3245, 2025). Orlando patients evaluating a local clinic should confirm that a licensed Florida physician personally reviews candidacy, rather than relying on a med-spa or franchise operating under delegated authority. Given the concentration of aesthetic and wellness clinics in Central Florida, verifying a clinic's licensure and product sourcing directly is a reasonable and worthwhile step before scheduling anything.

Frequently Asked Questions

Is exosome therapy FDA-approved?

No. As of 2026, no exosome product has received FDA approval for any use. Exosome products intended for a disease-related purpose are regulated as biologic drugs, which require a premarket review the agency has not yet granted to any product currently on the market (FDA, 2024).

What is the most serious risk of exosome injections?

The most serious documented risk is infection from a contaminated product, including bloodstream infections and joint infections that have required hospitalization. Because these biologic products cannot be sterilized after collection, contamination introduced during manufacturing carries directly through to the patient (Perkins et al., 2018).

How can I tell if an exosome product is legitimate?

Ask the clinic to name the manufacturer, provide a Certificate of Analysis confirming sterility and exosome content, and disclose whether the product is used under an FDA Investigational New Drug application. A clinic that cannot answer these questions directly should raise concern.

Are there alternatives to exosome injections with a longer track record?

Depending on the condition, alternatives with a longer regulatory track record include physical therapy, corticosteroid or hyaluronic acid injections, PRP, prescription hair-loss medications, and FDA-cleared aesthetic devices. Each carries its own risks and should be reviewed individually with a physician.

Can side effects appear after the visit is over?

Yes. Infection and allergic reactions can develop over the days following an injection, not only immediately afterward. Patients should monitor the injection site for several days and contact their provider promptly if fever, spreading redness, or drainage develops.

This article is for general patient education and does not replace an individualized medical evaluation. Exosome products discussed here are investigational outside FDA-approved clinical trials, and no exosome product is FDA-approved for joint pain, hair loss, skin concerns, or any other condition. Individual results vary, and no outcome, recovery time, or candidacy is guaranteed. Options are discussed based on the patient's individual goals and clinical circumstances following a medical evaluation.

Medically reviewed by Kenny Chantasi, DO.

References

Fla. Stat. § 458.3245 (2025). Stem cell therapy. Florida Senate. https://www.flsenate.gov/Laws/Statutes/2025/458.3245

Food and Drug Administration, Center for Biologics Evaluation and Research. (2019, December 6). Public safety notification on exosome products. FDA. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products

Food and Drug Administration, Center for Biologics Evaluation and Research. (2024, April 9). Consumer alert on regenerative medicine products including stem cells and exosomes. FDA. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes

Maher, S., & Gold, M. H. (2026). Regulatory, ethical, and safety considerations of exosome-based therapies in dermatology. Dermatological Reviews. https://doi.org/10.1002/der2.70071

Mahmoud, R. H., Peterson, E., Badiavas, E. V., Kaminer, M., & Eber, A. E. (2025). Exosomes: A comprehensive review for the practicing dermatologist. The Journal of Clinical and Aesthetic Dermatology, 18(4), 33–40.

Perkins, K. M., Spoto, S., Rankin, D. A., Dotson, N. Q., Malarkey, M., Mendoza, M., McNeill, L., Gable, P., & Powell, K. M. (2018). Notes from the field: Infections after receipt of bacterially contaminated umbilical cord blood–derived stem cell products for other than hematopoietic or immunologic reconstitution — United States, 2018. MMWR Morbidity and Mortality Weekly Report, 67(50), 1397–1399. https://doi.org/10.15585/mmwr.mm6750a5

Last medically reviewed: September 15, 2026

Related reading

• What Is Regenerative Medicine Used For?
• Is Regenerative Medicine Covered by Insurance?
• How Long Does Regenerative Medicine Take to Work?
• Are You a Candidate for Regenerative Medicine?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.